

Imipenem + cilastatin
Essential medicine status
General description

INN

Imipenem + cilastatin

ATC codes

[J01DH51](#)

Medicine type

Chemical agent

Antibiotic groups

[WATCH](#)

EML status history

First added in 1997 ([TRS 882](#)) for [Pseudomonas aeruginosa resistant to other antibiotic](#)

Added in 1997 ([TRS 882](#)) for [Antibiotic resistant Acinetobacter baumannii](#)

Removed in 2017 ([TRS 1006](#)) for [Pseudomonas aeruginosa resistant to other antibiotic](#)

Removed in 2017 ([TRS 1006](#)) for [Antibiotic resistant Acinetobacter baumannii](#)

Changed in 2021 ([TRS 1035](#)) for [Neutropenia](#)

Changed in 2021 ([TRS 1035](#)) for [Peritonitis](#)

Changed in 2021 ([TRS 1035](#)) for [Peritoneal abscess](#)

Changed in 2025 ([TRS 1064](#)) for [Multi-drug resistant Mycobacterium tuberculosis](#)

Therapeutic equivalent for

[meropenem](#) for [Multi-drug resistant Mycobacterium tuberculosis](#)

[meropenem](#) for [Neutropenia, unspecified](#)

[meropenem](#) for [Peritonitis, unspecified](#)

[meropenem](#) for [Peritoneal abscess](#)

Wikipedia

[Imipenem + cilastatin](#)

DrugBank

[Imipenem](#),

[Cilastatin](#)

Recommendations

Section

Watch group antibiotics

- Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Indications

[Pseudomonas aeruginosa resistant to other antibiotic](#) [Antibiotic resistant Acinetobacter baumannii](#)